8 results about "Attenuated Bacteria" patented technology

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

Described herein are recombinant, attenuated bacteria with an altered quorum sensing pathway. The recombinant bacteria are used for visualizing quorum sensing or immunizing marine organisms against infections by Vibrio spp.

This invention discloses the application of a glutamine-depleting engineered bacterium and its pharmaceutical composition. The engineered bacteria use attenuated bacteria with tumor-targeting capabilities as vector strains. The genome or plasmid of the vector strain integrates a therapeutic gene encoding glutaminase. This method achieves deep and continuous depletion of glutamine in the tumor, avoiding drug resistance caused by tumor metabolic compensation. The inhibition rate against c-Myc-overexpressing soft tissue sarcomas is significantly higher than that of small molecule inhibitors. Enzyme production is only carried out locally in the tumor, with no effect on normal tissues and no systemic toxicity. The engineered bacteria can penetrate the dense tumor matrix and colonize the tumor, solving the problem of poor tissue penetration of small molecule inhibitors. The engineered bacteria continuously multiply and produce enzymes in the tumor, achieving continuous release of glutaminase. The half-life is significantly longer than that of recombinant enzymes, eliminating the need for frequent dosing. The glutaminase optimized by protein engineering has significantly reduced immunogenicity.

The present invention relates to live attenuated bacteria which persist in a subject and their use in vaccine compositions. In particular, the invention is directed to mutant strain E.coli vaccines which are useful for poultry, and especially chickens.

The invention discloses an engineered immune cell as well as a preparation method and application thereof, the engineered immune cell is transformed through genetic engineering, and (1) a Gasdermin D N-terminal fragment (GSDMD-N) expression cassette controlled by a heat shock protein HSP70 promoter is stably integrated in a genome; (2) a photothermal conversion material and / or magnetic nanoparticles used for exogenous stimulation heating are loaded in the cells; and (3) attenuated bacteria and / or anti-tumor drugs for therapeutic loading; wherein the nucleotide sequence of the HSP70 promoter is as shown in SEQ ID NO: 1, and the nucleotide sequence of the GSDMD-N is as shown in SEQ ID NO: 2. According to the invention, accurate and controllable deployment of anti-cancer drugs such as bacteria loaded in immune cells at tumor sites is realized, good anti-tumor effect and high safety are achieved, and a new technical platform is provided for cell therapy and living microorganism anti-tumor therapy.

The application belongs to the technical field of drug co-delivery, and particularly relates to a nano platform based on attenuated bacterial outer membrane vesicles and capable of realizing co-delivery of siRNA and doxorubicin and a preparation method thereof. msbB extraction and purification of OMVs; synthesis of a targeting functional unit DSPE-PEG 2k -Angiopep-2; and finally, a ROS-responsive co-delivery nano platform AO@PTP / 47aD is prepared. The co-delivery nano platform prepared in the application has a small particle size, a uniform morphology and high biological safety, and does not cause obvious damage to various tissues and organs. The co-delivery nano platform can be used as a general platform for gene delivery and also as an immune activator, is suitable for intravenous injection and can completely overcome the immune resistance of glioblastoma.

The invention belongs to the technical field of biology, and discloses application of a novel attenuated bacterial vector for targeted delivery of Eya3 in tumor treatment, a gene recombination technology is adopted, a 202165relA gene is knocked out, sfgfp is inserted into the gene position, and the novel attenuated bacterial vector is obtained; according to the invention, a deformable core-shell nanostructure LNs is designed, and an Eya3-sgRNA plasmid is encapsulated in the LNs, so that an Eya3-sgRNA lipid nanoparticle is obtained; finally, the novel attenuated bacterial carrier is used as a carrier to be combined with the Eya3-sgRNA lipid nanoparticles, and the Sam-LNs drug delivery system is obtained. The compound provided by the invention is applied to tumor treatment drugs, has targeting property on tumor cells, and can reduce drug toxicity and improve clinical effects of drug stability.

Described herein are recombinant, attenuated bacteria with an altered quorum sensing pathway. The recombinant bacteria are used for visualizing quorum sensing or immunizing marine organisms against infections by Vibrio spp.